Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epidemiological Study to Evaluate the Prevalence of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)

NCT01081496 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01081496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epidemiological Study to Evaluate the Prevalence of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 31, 2010
Completion date
February 28, 2011
Enrollment
1,000 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer